lifestyle.mmminimal.com

Author: HOTH THERAPEUTICS, INC.

Hoth Therapeutics Announces Closing of $2.0 Million Registered Direct Offering

April 2, 2026
Hoth Therapeutics Announces $2.0 Million Registered Direct Offering

April 1, 2026
Hungary Approves Trial Expansion as HT-001 Meets Primary Endpoint in Interim Analysis with Patients Reaching ARIGA ≤1 by Week Six

April 1, 2026
Hoth Therapeutics Announces Issuance of Chinese Patent for Cancer Cell-Targeting Technology

March 31, 2026
Hoth Therapeutics Deploys OpenClaw™ AI Platform to Accelerate Drug Discovery

March 26, 2026
Hoth Therapeutics Reports Positive HT-001 PK, Safety, and Clinical Activity Data in Cancer Patients with EGFR Therapy-Associated Skin Toxicities Showing ~77% Increase in Drug Exposure and Minimal Systemic Absorption

March 24, 2026
Hoth Therapeutics Reports Positive Female Preclinical Data Showing HT-VA Restores Cholesterol Levels and Improves Lipid Metabolism in MASLD Model

March 10, 2026
Hoth Therapeutics Deploys OpenAI API to Advance Development of Orphan HT-KIT Oncology Program

March 4, 2026
HOTH THERAPEUTICS ACCELERATES HT-001 TRIAL ENROLLMENT WITH NEW CLINICAL SITE AS PATIENT DEMAND INCREASES

February 24, 2026
Hoth Therapeutics Receives U.S. Notice of Allowance for Novel Exon-Skipping Therapy Targeting Allergic Diseases

February 13, 2026